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Abstract  
 
 
THE ASSOCIATION BETWEEN CANCER-RELATED-FATIGUE, RESPONSE 
TO FATIGUE TREATMENT, AND CYTOKINES AND THEIR RECEPTORS, IN 
PATIENTS WITH ADVANCED CANCER 
      Publication No.________* 
Sriram Yennu, MD 
Supervisory Professor: James Reuben, MBA, PhD  
 
Background: Inflammation is implicated in the development of cancer related 
fatigue (CRF). However there is limited literature on the mediators of 
inflammation (namely), cytokines and their receptors, associated with clinically 
significant fatigue and response to treatment.  
Methods: We reviewed 37 advanced cancer patients with fatigue (≥4/10), who 
participated in two Randomized Controlled Trials, of anti-inflammatory agents 
(Thalidomide and Dexamethasone) for CRF. Responders showed improvement 
in FACIT-F subscale at the end of study (Day 15). Baseline patient 
characteristics and symptoms were assessed by FACIT-F, ESAS; serum 
cytokines [IL-1β and receptor antagonist (IL-1RA), IL-6, IL-6R, TNF-α and sTNF-
R1 and R2, IL-8, IL-10, IL-17] levels measured by Luminex. Data were analyzed 
using principal component analysis (PCA) [reporting cumulative variance 
(variance) for the first four components] to determine their association with 
fatigue and response to treatment.  
Results: Females were 54%. Mean (SD) was as follows for age, 61(14); 
baseline FACIT (F) scores, 21.4(8.6); ESAS Fatigue item, 6.5(1.9); and FACIT-F 
 v 
 
change, 6.4(9.7); ESAS (fatigue) change, -2 (2.41). Baseline median in pg/mL for 
IL-6, TNF-α, IL-1β were 31.9; 18.9; 0.55, respectively. Change in IL-6 negatively 
correlated with change in FACIT-F scores (p=0.02). Baseline CRF (FACIT-F 
score) was associated with IL-6, IL-6R and IL-17, Variance = 78% whereas IL-10, 
IL-1RA, TNF-α and IL-1β were associated with improvement of CRF, 
Variance=74%. Conversely, IL-6 and IL-8 were associated with no improvement 
or worsening of CRF, Variance= 93%.  
Conclusions: Change in IL-6 negatively correlated with change in FACIT-F 
scores. IL-6, IL-6R and IL-17 are associated with CRF while IL-6 and IL-8 were 
associated with no improvement of CRF. Further studies are warranted confirm 
our findings. 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 vi 
 
TABLE OF CONTENTS  
 
Acknowledgements ..................................................................................... iii 
Abstract ........................................................................................................ iv 
List of Tables ................................................................................................ ix 
Chapter 1. Introduction ................................................................................ 1 
A. Background ............................................................................................. 1 
B. Study Rationale ..................................................................................... 11 
C. Hypotheses ........................................................................................... 13 
D. Study Aims............................................................................................ 13 
Chapter 2. Research Design and Methods ............................................... 14 
A. Study Design ......................................................................................... 14 
B. Inclusion Criteria ................................................................................... 14 
C. Exclusion Criteria .................................................................................. 14 
D. Patient Screening and Recruitment ...................................................... 15 
E. Treatment Plan………………………………………………………………..17 
F. Study Outcome Measures ..................................................................... 18 
G. Statistical Analyses ............................................................................... 21 
Chapter 3. Results ...................................................................................... 23 
Chapter 4. Discussion ................................................................................ 29 
Limitations ................................................................................................. 32 
 vii 
 
Conclusions ............................................................................................... 33 
Appendix ..................................................................................................... 34 
A. Study Forms: Memorial Delirium Assessment Scale ............................ 34 
B. Study Forms: Functional Assessment of Cancer Therapy .................... 38 
C. Study Forms: Edmonton Symptom Assessment Scale ......................... 41 
D. Cyokine Assessement and Methods ..................................................... 42 
E. Study Consent……………………………………………………………….. 47 
F. Treatment Plan and Standard operating procedure…………………….  60 
Bibliography ................................................................................................ 61 
Vita …………………………………………………………………………………..71 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 viii 
 
 
 
List of Illustrations  
Figure 1. Interaction between various cytokines and hypothalamic –pituitary 
adrenal axis……………………………………………………………..................5  
Figure 2. Schematic Diagram Illustrates the Interactions between Tumor, Tumor 
Byproducts, Brain, Nerves, Cytokines, Symptoms and Anti-Inflammatory Agents 
(Thalidomide and Dexamethasone) ............................................................... 11 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 ix 
 
 
 
 
List of Tables  
Table A. Corticosteroids (dosage and duration) in the management of Cancer 
Related Fatigue................................................................................................9 
Table 1. Patient Characteristics ..................................................................... 24 
Table 2. Association of Baseline FACIT-F and Baseline Cytokines............... 26 
Table 3. Association of Baseline Fatigue Cluster and Baseline Cytokines .... 26 
Table 4. Association of Change in FACIT-F and Change in Cytokines ......... 27 
Table 5. Association of Change in Fatigue Cluster and Change in Cytokines ... 
………………………………………………………………………………………...27 
 
 1 
 
Chapter 1. Introduction 
A. Background 
A. 1. Fatigue in patients with cancer 
Fatigue is the most common chronic and severe symptom associated with 
cancer [1-3]. Fatigue is often the one symptom most likely to interfere with 
physical and social activities. In cancer patients receiving cancer-related 
treatment, the frequency of fatigue exceeds 75%. Among the cancer related 
symptom, fatigue is the most severe symptom and has most profound influence 
on patients’ quality of life [1]; more than 91% of affected patients reported that 
fatigue interfered with their ability to lead normal lives.  Sixty-one percent of 
patients reported that fatigue affected not only pain but their performance at 
work; fatigued patients were absent an average of 4.2 days per month during and 
immediately after treatment, because of fatigue [2]. Despite its effect on all 
aspects of quality of life, cancer-related fatigue is under-treated or overlooked by 
oncologists. 
 
A. 2. Fatigue and advanced cancer 
Previous research has shown that patients with advanced cancer develop severe 
physical and psychosocial symptoms as a result of cancer and its treatments. 
The frequency of cancer-related fatigue (CRF) varies from 60% to 90%. CRF is 
more severe in advanced stages as compared to early disease stage [4]. CRF 
can prevent these patients from receiving effective cancer therapy. Despite the 
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prevalence of CRF, severity and effects on the quality of life of patients with 
advanced lung cancer, there are limited treatment options available. Prior studies 
have revealed that CRF has a multifactorial etiology in these patients [5]. Several 
factors are significantly associated with CRF, including: anxiety, depression, 
pain, anorexia/cachexia, drowsiness, sleep disturbances, and cognitive 
functioning [6]. In recent years, several cytokines and other pro-inflammatory 
mediators, produced by the host in response to the presence of cancer have 
been found to be associated with symptoms such as fatigue, pain, cognitive 
impairment, depression, cachexia, and sleep disorders [7-9]. The lack of effective 
treatment is due to limited understanding of this complex pathophysiology and 
inability to target the known complex mechanisms of CRF adequately. 
 
A. 3. The Role of Cytokines and fatigue 
Origination of the cytokines and general function: Cytokines are polypeptides 
secreted by the immune cells (T –cells, macrophages) that mediate 
communication between cells. The immune cells are activated in patients with 
cancer by cancer, cancer complications and its treatment. The T-cell subsets 
have a key role in the regulation of inflammatory responses. Immune cells via 
inflammatory cytokines activate the transcription factor, Nuclear factor- Kappa B 
[NF-κB], a critical regulator of pro-inflammatory responses.  NF-κB can be found 
in the cytoplasm of all cell types in its inactive form, associated with inhibitory 
proteins known as inhibitors of NF-κB (IκB).  NF-κB is also inactivated by the 
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induction of IκB that prevents the nuclear translocation of NF-κB and the 
subsequent transcription of inflammatory cytokines. [10].   
 
Functions of inflammatory cytokines: Interleukin (IL)-1β is a pro-inflammatory 
cytokine. It belongs to the gene family IL-1α and IL-1 receptor antagonist (IL-
1RA). These molecules bind to two receptors (type I and type II). Upon activation 
by the ligand, the type I receptor complexes with accessory protein, which results 
in signal transduction. IL-1 along with IL-6 and Tumor necrosis factor–alpha 
(TNF-α) induce the synthesis of neurotransmitters such as serotonin, 
Indoleamine 2,3 dioxygenase, p38 mitogen-activated protein kinase, dopamine 
and glutamine [9]. These neurotransmitters are involved in modulation of 
symptoms such as fatigue, depression which constitute the sickness behavior. In 
addition these cytokines modulate pattern of secretion of hypothalamic -pituitary 
adrenal axis [HPA] secretion that characterizes cancer related fatigue[ 9].  IL-6  is 
secreted by T cells and macrophages. It acts as both pro- and anti-inflammatory 
cytokine. IL-6 exhibits its action via a receptor complex consisting of specific IL-6 
receptor and signal transducing subunit(gp130) by a process called trans-
signaling[11].  
TNF-α is an inflammatory cytokine with primary action via two receptors TNF R1 
and TNF R2. Upon contact with a ligand, the TNF receptors form trimers which 
lead to conformational changes on the receptor leading to activarion of NF-kB, 
MAPK and induction of death signaling pathways. In conjunction with IL-1β and 
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IL-6, TNF-α modulate pattern of secretion of neurotransmitter and hypothalmic-
pituitary-adrenal axis[HPA] secretion as described earlier.  
 The interleukin (IL)-10 family of cytokines and the closely related interferon (IFN) 
family of cytokines form the larger major histocompatabilty complex (Class II 
cytokine family. IL-10 has strong anti-inflammatory properties by deactivation of 
macrophages[12]. It downregulates the expression of Th1 cytokines such as 
interferon –gamma, TNF-α, MHC class II antigens, and costimulatory molecules 
on macrophages. It enhances B cell survival, proliferation, and antibody 
production. Its action counter balances the action of elevated IL-1 and/ or TNF-α 
to maintain homeostasis [13].  
 
Downstream effects of various cytokines: 
The biological functions of the cytokines are achieved by binding with high affinity 
and specificity to cell surface receptors, thereby triggering signal transduction 
cascades that regulate cellular function (e.g., activation, proliferation). 
 
The cytokines effects are via tyrosine kinases such as Janus kinase(jaks). The 
Jaks  via its Phosphotyrosine- containing motifs bind to the receptors of signaling 
proteins including Signal transducers and activators of transcription(STAT) 
proteins. Upon binding the STAT proteins undergo phoshorylation  and 
dimerization. On transfer to nucleus the STAT proteins bind to the target gene 
promoters and regulate transcription by binding to CBP protein or  p300 co-
activator molecules resulting in unwinding of DNA[10].  
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 When an acute inflammatory response is triggered [e.g., Lipopolysaccaride and 
endotoxin], the immune cells such as macrophages activate the nuclear NF-kB 
which in turn lead to activation of the IL-1β, IL-6, and TNF-α[See Fig 1]. Finally 
IL-6 inhibits IL-1β and TNF-α production not only by directly inhibiting the release 
their synthesis and release [14], but also by stimulating the induction of IL-1β 
receptor antagonist, IL-1RA, and sTNF-αRI [15]. This action counter balances 
the action of elevated IL-1 and/ or TNF-α to maintain homeostasis [13]. 
Interleukins such as IL-6 are pleiotropic and exhibit overlapping function due to 
sharing of common signal transduction pathways e.g., Functional receptor 
complexes for interleukin-6 family of cytokines share gp130 as a component 
critical for signal transduction [14].  
Fig. 1. Interaction between various cytokines and hypothalamic –pituitary 
adrenal axis [Illustration compiled based on the literature review from 
Schindler et al., Vitkovic, Garg et al. and capuron et al.[9,10,13,and 14] 
+
_
IL -1β , TNF-αIL -6
Activated HPA axis
Secretion of  GHRH/CRH 
by the hypothalamus
Plasma
ACTH
Cortisol
GR
Nuclear NF-kB
I-kB
IL-1RA, sTNFR
HIV-1 Activated Immune Cells
Fatigue and Sleep DisturbanceCancer relat d Fatigue
Macrophag s/ Monocyt s
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The pleiotropic and overlap in function of various inflammatory cytokines due to 
same cell distribution of their receptors and sharing common downstream 
signaling pathways [10]. For example, following induction of external stimuli, 
TNF-α and other cytokines such as IL-1β, IL-6, and TNF-α stimulates the 
production of various inflammatory cytokines such as IL-1, IL-6, IL-8, IFN and 
TGF-β. By the modulation of receptor expression of one cytokine by other or 
interactions at the level of signal transduction, gene expression or 
posttranslational level, the interactions of the cytokines can be synergistic (e.g., 
TNF-α -IL-1 interactions) or antagonistic (TNF-α and TGF-β) [16] 
 
Prior studies have proposed the role of inflammatory cytokines such as IL-6 in 
mediation of cancer related fatigue via various mechanisms including: (a) Neuro-
endocrine activation the hypothalamic-pituitary-adrenal (HPA) axis, leading to the 
release of Growth hormone releasing hormone (GHRH) and corticotrophin-
releasing hormone (CRH) by the hypothalamus [8,9].  Changes in the balance 
between GHRH and CRH are the principal regulators of CRF. One mechanism 
by which the cytokine exposure may influence HPA axis function is through 
inhibitory effects on the receptor for glucocorticoids, cortisol, the end product of 
HPA axis activation [9]  (b) Effects on neurotransmission in the brain: Studies in 
depression [9], have indicated that inflammatory cytokines effect symptoms such 
as depression, fatigue by alteration synthesis and uptake of neurotransmitters 
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such as serotonin, indoleamine 2,3 dioxygenase(IDO), p38 Mitogen activated 
protein kinase (MAPK), dopamine, and glutamate[9]. One of the mechanism by 
which inflammatory cytokines alters the secretion of neurotransmitters such as 
serotonin is by enhancing the activity of serotonin transporter (SERT). 
 
Studies on relationship between cancer-related-fatigue and cytokines: 
Cytokines have been associated with the presence of tumors, co-morbidities 
such as infections and the effects of cancer treatments including radiation 
therapy and cytotoxic therapy [7-9]. In recent years, it has become evident that 
many cytokines have powerful effects on the brain [9].  Animal models of 
symptoms such as pain and cachexia, and clinical studies of immunotherapy in 
which pro-inflammatory cytokines are administered to patients with various 
cancers have provided important insights into the central effects of these agents 
[9]. 
 
Sickness behavior [fatigue, depression, sleep alteration] is typically associated 
with behavioral changes seen in laboratory animals suffering from microbial 
infections [9,10].   IL-1β, IL-6, TNF-α were found to mediate sickness behavior 
[9,10]. IL-1β, IL-6, TNF-α is known to cause the symptoms of sickness behavior 
by it action in the brain, more specifically through the HPA axis [7,8,17,18]. 
Various studies have shown an association between severity of fatigue and 
increase in cytokines. Greenberg et al [19] in a longitudinal study for 9 weeks in 
15 cancer patients with prostate cancer receiving radiation therapy found a 
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significant correlation of fatigue with IL-1B. Ahlberg et al. [20] in a longitudinal 
study in 15 patients with uterine cancer receiving radiation therapy found a 
significant negative correlation of fatigue with IL-6. Meyers et al.[21] in 54 
patients with AML/MDS found significant correlations of IL-1RA and IL-6 with 
severe fatigue. Rich et al. [18] in 80 advanced colorectal cancer patients found a 
significantly positive association between fatigue and transforming growth factor 
(TGF-α). Wang et al. [22] in 62 advanced lung cancer patients receiving radiation 
therapy found serum IL-6 levels to be related to the increased mean levels of the 
most severe symptoms (pain, fatigue, disturbed sleep, lack of appetite, sore 
throat). Inagaki et al. [23] in 46 patients with advanced cancer found plasma IL-6 
levels correlated with the fatigue. 
 
A.4. Corticosteroids and fatigue  
Dexamethasone is a synthetic glucocorticoid. It exhibits potent anti-inflammatory, 
immunosuppressant activity with minimal mineralocorticoid properties. The action 
of dexamethasone on cytokines such as IL-6, IL-1β, IL-8, IL-10 is by its effect on 
transcription factor NF-κb which is instrumental in activation of multiple genes[25-
30]. Corticosteroids are hypothesized to decrease fatigue by decrease of the 
cytokines IL-1, IL-6, TNF-α [17-23].  IL-1, IL-6, TNF-α are associated with the 
causation of fatigue [7-9]. Table A. shows various studies in which corticosteroids 
were used to manage cancer related fatigue. 
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Table A.  Corticosteroids (dosage and duration) in the management of cancer 
related fatigue [29-42] 
Author 
Number 
of 
patients 
Treatment 
Duration 
(days) 
Study 
Drug* 
Equivalent 
Dexamethasone 
daily dose (mg) 
Della Cuna 1989** 40 56 MP 23 
Vecht 1994** 96 28 DM 4-16 
Bruera et al 1995** 40 14 MP 6 
Popiela et al** 173 56 MP 23 
Italian group 2000** 708 5 DM 8 
Akira Inoue 2003** 68 6 DM 8 
JR Hardy 2001 160 22 DM 12 
Mercadante 376 26 DM 4-16 
Bruera 2004** 51 7 DM 20 
     
  *MP= Methylprednisolone, DM=Dexamethasone 
  ** Randomized, double blind placebo controlled studies 
 
A.5. Thalidomide and fatigue  
Studies have identified several side effects of interferon therapy, including flu-like 
symptoms such as somnolence and cancer related fatigue [9]. Sickness behavior 
related to cancer treatment often manifests itself through the symptoms of CRF 
[8-10]. It has been reported that cancer related symptoms such as fatigue, 
depression are associated with an increase in IL-1, IL-6 and TNF-α [8,9]. Prior 
studies show that Thalidomide improves symptoms contributing to fatigue 
including sleep disturbance, anorexia and activity [5,32]. Thalidomide selectively 
modulates the release of such as TNF-α(inhibits), IL-10(increased production) 
and other cytokines and may potentially improve CRF [31,32]. 
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A.6. Theoretical construct[Fig.2.] 
Previous research has shown that patients with cancer develop severe physical 
and psychosocial symptoms [33,34]. The prevalence rates of the many different 
symptoms reported by advanced cancer patients include fatigue 90%, followed 
by pain 41%-76%, anorexia 85%, depression 33%-40%, anxiety 57%-68%, 
nausea 24%-90%, constipation 65%, sedation/confusion 46%-60%, and dyspnea 
12%-58% [33,34].  Various studies in patients with cancer showed that fatigue 
usually occurs concurrently with other symptoms namely fatigue, anxiety, 
depression and sleep disturbance and feeling of wellbeing which conform a 
symptom cluster (Fatigue cluster) [35]. The brain is the ultimate organ where 
symptoms are perceived [8,9,and17]. Recent studies showed that cancer 
patients have a surge of inflammatory cytokines which play a predominant role in 
the causation of fatigue and its cluster [7]. This change in cytokines occurs as a 
result of complex interactions between the cancer and the host. It has been 
noted that inflammatory cytokines can influence the stimulation of afferent nerves 
at the periphery and some of the central synaptic activity at the dorsal horn and 
in the brain cortex [9]. Also involved in the causation of fatigue is decreased 
muscle function, tumor by products and the other symptoms that constitute the 
cluster i.e., fatigue, anxiety, depression and sleep disturbance [35].     
 11 
 
 
 
Fig.2.Schematic diagram compiled based on the literature review of Dantzler et 
al sickness behavior [8,9,17], illustrates the interactions between tumor, tumor 
by-products, brain, nerves, cytokines, symptoms and anti-inflammatory agents 
(thalidomide and dexamethasone). 
 
 
B. Rationale:  CRF is the most common distressing and severe symptom in 
patients with cancer, impacting their quality of life. Unfortunately despite the 
burden of CRF, there are no proven treatments for it in patients with advanced 
cancer. The limited treatment options are due to limited understanding of its 
complex pathophysiology. A number of studies have shown an association 
between inflammatory markers and fatigue in cancer patients [7-17, 50].  In a 
pooled analysis of eighteen studies that met the quality criteria, Schubert et al. [7] 
found a significant positive correlation between CRF and IL-6, IL-1 receptor 
antagonist (IL-1RA), and neopterin. However, there is limited published data to 
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show whether improvement in fatigue scores with targeted treatment results in 
decrease in the elevated levels of inflammatory serum cytokines. As it may not 
be possible to design a study to investigate the causative role of Inflammatory 
cytokines for CRF due various confounders such as patient, disease and 
treatment factors involved, a more feasible design is to investigate the 
associations between change in inflammatory cytokines with treatment of anti-
inflammatory agent/s to treat fatigue. The ultimate goal is to find treatments for 
CRF based on targets modulating the inflammatory markers. 
 
The objective of this study was to obtain preliminary data to characterize the 
inflammatory cytokines associated with fatigue in patients with advanced cancer 
and assess the change inflammatory cytokines with change in fatigue scores with 
fatigue treatment. The other exploratory objectives were to determine the 
association of fatigue cluster with various inflammatory cytokines as the 
manifestation of fatigue occurs concurrently with other symptoms such as 
anxiety, depression, sleep, and feeling of well-being which collectively 
constitutes, fatigue cluster. Fatigue cluster is believed to contribute to the 
symptom burden in patients with advanced cancer which impact quality of life. 
We also examined the effects of the anti-inflammatory agents (thalidomide, and 
dexamethasone) on fatigue and the inflammatory cytokines. The preliminary data 
from this study will be utilized to develop treatment strategies to alleviate fatigue 
and improve quality of life as well as to help patients to tolerate treatment, in 
general.   
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C. The Hypothesis:  
 
I hypothesized that anti-inflammatory agents by their action on 
inflammatory cytokines are associated with change (decrease) in severity 
of cancer related fatigue. 
 
Specific Aims: 
I planned to test this hypothesis and accomplish the objectives of this 
project by performing the following specific aims: 
a) To determine the mediators of inflammation (namely), cytokines (IL-1β, 
IL-6, IL-8, IL-17, TNF-α and IL-10] and their soluble receptors, associated 
with clinically significant fatigue s defined as fatigue score of ≥ 4/10 in a o-
10 scale.  
b) To determine the mediators of inflammation (namely), cytokines (IL-1β, 
IL-6, IL-8, IL-17, TNF-α & IL-10] and their receptors, associated response to 
treatment. 
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CHAPTER II. Research Design and Methods 
We accessed the original data for this project from two prospective clinical trials: 
protocol 2005-0816 Dexamethasone for symptom distress in advanced cancer 
[NCT00489307] and The Effects of Thalidomide on Symptom Clusters, protocol 
2005-0980 in patients with advanced cancer [NCT00379353]. We reviewed the 
demographic information (such as age, gender, ethnicity, and cancer diagnoses), 
Edmonton Symptom Assessment System (ESAS), Memorial delirium 
assessment scale (MDAS), and Functional Assessment of Chronic Illness 
Therapy-Fatigue (FACIT-F) scores at baseline and day 15. In both the studies, 
patients who agreed to participate in the study were given a 14-day supply of 
study medication.  
We received approval from The University of Texas MD Anderson Cancer Center 
Institutional Review Board for the present study and all patients provided written 
informed consent at the time of their initial enrollments. Due diligence was taken 
to protect the patients' confidentiality. 
Performance Sites 
Clinical setting  
Patients with advanced cancer were recruited from The University of Texas MD 
Anderson Cancer Center (MDACC; a comprehensive cancer center), Lyndon B. 
Johnson General Hospital (LBJ: Harris county hospital) and Four Seasons 
Hospice and Palliative care, Flat Rock, North Carolina(Four Seasons Hospice). 
The physicians identified potentially eligible patients to participate in this study.  
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Research staff 
The research staff in the Department of Palliative Care and Rehabilitation 
Medicine includes a manager of clinical protocol administration, a research 
nurse supervisor, three research nurses and a data coordinator. Our group 
has conducted multiple clinical trials related to symptom management, quality 
of life and communications between patients and physicians. 
 
Patients Screening and Recruitment 
Patients with advanced cancer were recruited from MDACC, LBJ and Four 
Seasons Hospice. Inclusion criteria for the current study included the 
following: a fatigue score 4 on a scale of 0–10 (0 = no fatigue, 10 = worst 
possible fatigue) during the previous 24 hours; No clinical evidence of 
cognitive failure as evidenced by MDAS score of ≥13 at baseline or normal 
MMSE score (that is, a score ≥24); and a hemoglobin level ≥10 g/dL. 
Exclusion criteria were of use of steroids (including dexamethasone, 
Megestrol), thalidomide or lenalidomide, neutropenia, sepsis and/or acute, 
chronic, or ongoing infections, pregnant and lactating women and all major 
surgeries such as thoractomy, that requires wound healing within last 2 
weeks.  
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Patient rights and confidentiality  
Patients were informed that refusing to participate in the study or electing to 
terminate their participation will not affect their current treatment plan. The 
patients were given a written and verbal description of the study during the 
informed consent teaching interview. Guidelines regarding Institutional Review 
Board, Human Rights Protection were strictly followed. 
 
Study subjects signed an IRB-approved written informed consent form after 
having the study explained to them in person by a physician. Patients were 
assured that that lack of participation in the study would not bear a relationship to 
their care for cancer or its symptoms. Circumstances of obtaining informed 
consent were documented in patient medical records. Informed consent was 
obtained in the language preference of the potential subject. When necessary, 
professional translators, and not family members, were utilized to obtain written 
informed consent. 
 
We maintained confidentiality by assigning a study number to all study subjects. 
Data collected was identified and tracked using this number. No names or other 
identifying information were attached to the data collection.  
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Screening and accrual process is described in detail below: 
a) The research nurse screened the electronic medical records of outpatient 
center visits of all patients of collaborators for the patients meeting the 
eligibility criteria.  
b) The research nurse notified the Sriram Yennu MD, principal investigator 
and the collaborator of the eligibility.  
c) Eligible patients were approached by the research nurse to obtain 
consent.  
d) Consented patients were enrolled in the study. Reason for inability to 
consent was documented in the screening log. 
e) Weekly protocol meeting chaired by the PI, included the research nurse, 
research manager, protocol manager, data coordinator to review the 
screening, accrual, status of the patients on the study including adverse 
events, serious adverse events, dropouts. 
f) Annual review of the data was conducted by the data safety and 
monitoring board at MD Anderson Cancer Center. The IRB conducted an 
annual review of the protocol in regards to patient protection, accrual, and 
adverse events. Department and Intuitional audits were performed in order 
to ensure data quality.  
Study treatment Plan 
In the study, consenting eligible patients received study medication for 14 days.  
Exam (including history including FACIT-F, ESAS and toxicity assessment were 
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done at baseline, and Day 15 [± 3 days]. Serum cytokines (IL-1β, IL-6, IL-17, 
TNF-α, IL-10, IL-8, and corresponding receptor levels), on baseline and Day 15 
[± 3 days] were collected. 
 
Study Medication strength, frequency: 
• The dose of dexamethasone was 8mg a day.  
• The dose of Thalidomide is 100mg a day.  
 
Outcome Measures  
 
1. Baseline demographics were collected from each patient and/or health records 
just prior to initiation of study intervention, and included the following: 
• Demographics (date of birth, gender, race) 
• Cancer diagnosis (date of diagnosis, cancer type, treatments received) 
• Fatigue measures: Functional Assessment for Chronic Illness Therapy-
Fatigue (FACIT-F) (see below for details) 
 
Cytokine measures (See below for principles and Method in Appendix D):  
 
Cytokines such as IL-1, IL-6, TNF-α, IL-10, IL-8, IL-17 (serum) and their 
receptors have been reported to correlate with other symptoms such as fatigue 
anorexia/cachexia, nausea, pain, depression, cognitive impairment and sleep 
disorders in cancer patients.  
 
In this study, we measured the levels of IL-1, IL-6, TNF-α, IL-10, IL-8, IL-17 
(serum) and their receptors at baseline, days15 [± 3 days]. The serum samples 
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were stored frozen for subsequent cytokine profile. Serum samples were 
assayed. The cytokine profiles were correlated with the intensity of symptoms 
and for the responsiveness or failure to respond to study medication. Pro-
inflammatory cytokines IL-1, IL-6, TNF-α, IL-10, IL-8, IL-17 (serum) and their 
receptors were measured in the serum of patients using commercially available 
Luminex kit (Biosource Inc.). The Multiplex Bead Immunoassay was being used 
to measure serum levels of IL-1, IL-6, TNF-α, IL-10, IL-8, IL-17 and their 
receptors. Serum IL-10, IL-1β, IL-1RA, IL-6R, TNF-RI, TNF-R2 were also 
analyzed using ELISA, as the data obtained were undetectable levels in majority 
of study patients using Multiplex Bead Immunoassay. 
 
Measure for Delirium: 
• Memorial Delirium Assessment Scale (MDAS) (Appendix A) is a 10 item 
questionnaire validated in cancer patients for assessment of delirium (51).  It 
can be administered by a physician, a nurse or a research coordinator, 
assigning a score between 0 and 30.  A score of >13 is suggestive of 
delirium. This measure was used to assess the eligibility to the clinical study, 
as patients with delirium are not eligible to participate in the study. 
   
 Fatigue Measures: 
 
The Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F) 
(Appendix B): The FACIT-F fatigue subscale has been used primarily in 
cancer patients to measure fatigue (52). The subscale consists of 13 items. 
Patients rate the intensity of fatigue and its related symptoms on a scale of 0-
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4, from 0 “not at all” to 4 “very much”. The scoring is 0-52 points, a higher 
score (e.g., 48) indicates low intensity of fatigue and a low score (e.g., 11) 
indicates severe fatigue. Test-retest reliability coefficients for the fatigue 
subscale have ranged from 0.84-0.90. This scale has demonstrated strong 
internal consistency (alpha=0.93-0.95). This assessment was performed at 
baseline, and day 15. 
The Edmonton Symptom Assessment System (ESAS) (Appendix C): This tool 
was designed by our group to assist in the assessment of ten symptoms 
common in cancer patients: pain, fatigue, nausea, depression, anxiety, 
drowsiness, shortness of breath, appetite, sleep, and feelings of well-being 
(53,54).  The severity at the time of assessment of each symptom is rated 
from 0 to 10 on a numerical scale, 0 meaning that symptom is absent and 10 
meaning that it is of the worst possible severity. The instruments and 
techniques are both valid and reliable in the assessment of the intensity of 
symptoms in cancer populations. Symptom assessment was evaluated at 
baseline, and day 15. Fatigue with other symptoms such as anxiety, 
depression, sleep disturbance and feeling of wellbeing as assessed by ESAS 
was used to calculate Fatigue cluster [FADSW] [35]. 
 
• Methods for collection storage analysis and interpretation of cytokines 
To study the effect(s) of study drug, levels of inflammatory cytokines 
(interleukin-6 [IL-6], IL-8, IL-17,IL-10, IL-1β, and TNF-α), and cytokine 
receptors (IL-6R, IL-1RA and soluble TNF-receptors (sTNF-R1, sTNF-R2) 
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were measured at baseline, and day 15 of treatment in 45 patients who 
consented for additional blood collections for optional correlative studies. 
 
Collection and Storage of serum 
Peripheral blood was drawn from all subjects and serum sample are stored as 
per protocol [described in detail in Page 55, Appendix D and reference 55].   
 
 
Principles and Methods of Multiplex Assay: Appendix: D 
 
Statistical Analysis: 
Distributions of data were examined by analyzing the data graphically. If the data 
appeared to be non-normally distributed, then transformations to the data were 
considered, or non-parametric equivalents of the parametric tests described in 
the results below were used for analyses. 
 
To determine the relationships between serum cytokines (IL-6, IL-8, and IL-10, 
IL-1β, IL-17 and TNF-α), and cytokine receptors (IL-6R and soluble TNF-
receptors (sTNF-R1, sTNF-R2), IL-1RA and fatigue at baseline and 14 days of 
treatment, descriptive statistics for each variable were presented in tables. In 
addition, we correlated cytokines and the fatigue [FACIT-F, ESAS fatigue item 
]and fatigue cluster score using Spearman correlation coefficients as the data 
was not normally distributed. We also reported the ratio of IL-6/IL-10 ratio as both 
these cytokines constitute the predominant pro-inflammatory and anti-
inflammatory response, their interaction may play a important role in the clinical 
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manifestation of symptoms of cancer and its treatment such as fatigue and 
fatigue clusters, the outcome of our study as evidenced in prior studies in 
neonates, major surgeries, burns or trauma [56, 57].  
 
We used principle component analysis (PCA) to determine which symptoms 
cluster together to form a principle component and if other variables, such as 
cytokines, will also load highly on individual factors. Our goal was to discover the 
underlying, unobservable factors (latent factors) associated with the 
interrelationships of these variables. We included analyses of scores at two 
points in time. Time one is at baseline, when all patients have not yet received 
study medication; time two will be at day 15. For analyses at time two, we 
performed PCA in whom we had observed improved fatigue (defined as atleast 1 
point improvement in the FACIT-F fatigue scores) and those without improved 
fatigue.  Each PCA included the serum cytokines (interleukin-6 [IL-6], IL-8, and 
IL-10, IL-1β, and TNF-α), and cytokine receptors [IL-6R and soluble TNF-
receptors (sTNF-R1, sTNF-R11)], IL-1RA and the FACIT-F fatigue subscale 
score. 
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CHAPTER III. Results 
The median age of the 45 patients was 62 years; the most common primary 
cancers were gastrointestinal and lung. [Table 1] 
 
Table 1.a. shows descriptive data of demographic characteristics, baseline 
fatigue scores (FACIT-F, Fatigue subscale and ESAS, Fatigue item) and serum 
inflammatory cytokines levels. 
The median change of fatigue at the end of study (primary endpoint) was 6 points 
(FACIT-F) and -2 points (ESAS-Fatigue item).  
Table 1.b. shows that the serum levels of the control subjects was less than 
fatigued advanced cancer patients. A Mann-Whitney U test determined the 
difference between the control and fatigue patients of the study to be significant 
for IL-6, TNF-α, IL-8, IL-17, and IL-1RA. However there was no difference in the 
levels of IL-1β and IL-10. 
 
Table 2 shows significant association between baseline fatigue as assessed by 
FACIT-F and ESAS- fatigue item and fatigue cluster (Fatigue, anxiety, 
depression, sleep disturbance and feeling of well-being). However no association 
was found between baseline fatigue (FACIT-F) and baseline serum inflammatory 
cytokines and receptors {IL-6, IL-8, and IL-10, IL-1β, and TNF-α), (IL-6R, IL-1RA 
and soluble TNF-receptors (sTNF-R1, sTNF-R2)}. 
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Table 3 shows significant association between baseline fatigue cluster (FADSW) 
and baseline FACIT-F scores, serum cytokines IL-10, IL-6/IL-10 (pro-
inflammatory and anti-inflammatory ratio).  
Table 1. a.  Patient characteristics(n=45) 
 
 
 
 
 
 
 
 
 
 
 
 
 
a
 brain, Lymphoma/myeloma/leukemia, gynecological,  
no evidence of disease (NED), skin, unknown primary, melanoma. 
* Fatigue, anxiety, depression, sleep disturbance and feeling of well-being cluster 
 
Table 1.b. Baseline fatigue scores and change in fatigue scores after 14 days of treatment 
 
 
FACIT-F=Functional assessment of cancer illness therapy- fatigue 
ESAS=Edmonton symptom assessment scale 
Fatigue cluster= fatigue, anxiety, depression, sleep disturbance and feeling of well-being 
 
 
 
 
 
 
 
 
 
 
 
 
 
Patient characteristics Mean (SD) Median 
Age 61(14) 62 
Sex Female 54%  
Race 
 
White 
Hispanic  American 
Asian  American 
African American 
 
 
 
60%   
6%  
26%  
8% 
Primary cancer diagnosis (%) 
 
Breast 
Gastrointestinal 
Genitourinary 
Sarcoma 
Lung/head and neck 
 Others a 
 
 
3 (6%) 
11(24%) 
4 (8%) 
6(13%) 
10(22%) 
11(24%) 
 
Fatigue  scale (n=45) Mean(SD) Median 
FACIT-F subscale  21.46(8.68) 22 
ESAS – Fatigue item 6.55(1.99) 7 
Fatigue cluster (FADSW)* 22.26(8.7) 21 
ESAS-F CHANGE -2(2.41) -2 
FACIT-F CHANGE 6.4(9.73) 6 
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1 .c. Baseline cytokine and receptors levels in advanced cancer patients 
with clinically significant fatigue(n=45 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 1.d. Comparison of serum baseline cytokine levels with Normal controls 
 
 
 
* Mann-Whitney U test (two-tailed),  
Ψ
 A Mann-Whitney U test showed this difference to be significant. 
 
 
 
 
 
 
 
 
 
 
 
Baseline serum Cytokine 
and Receptor levels(pg/ml) 
Mean(SD) Median Range 
IL-6 67.57(122) 31.96  
IL-1RA 725.7(542) 547  
TNF-α 32.15(48.6) 18.91  
IL-6R 14697(14780) 8812.5  
IL-1 β 5.7(4.41) 0.55  
IL-8 403.7(1012.2) 82.16  
IL-10 11.77(15.5) 4.9  
TNFR1 1511(973.7) 1309  
TNFR2 6914.6(6196) 5445.6  
IL-17 82.5(165) 22.42  
Serum 
cytokines 
N= 
normal 
Mean(SD)
(pg/mL)  
in normal 
controls 
Median 
(pg/mL)  
in normal 
controls 
N=fatigued 
advanced 
cancer 
patients  
Mean(SD) 
(pg/mL) in 
fatigued 
advanced 
cancer 
patients   
Median (pg/mL)  
in fatigued 
advanced 
cancer patients  
P-value* 
IL-6 52 14.3(21) 7.08 45 67.57(122) 31.9 <0.001Ψ 
TNF-α 42 14.6(50.9) 5.9 45 32.15(48.6) 18.9 <0.001Ψ 
IL-8 42 30.3(36.7) 16.7 45 403.7(1012) 82.1 <0.001Ψ 
IL-17 42 30(58) 7.2 45 82.5(165) 22.4 0.03 Ψ 
IL-1RA 19 265(139) 231 39 725.7(542), 547 0.01 Ψ 
IL-1β 8 19.5(42.3) 3.4 34 5.7(4.41) 0.55 0.65 
IL-10 15 50.5(137.
3) 
2.9 38 11.77(15.5) 4.9 0.48 
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Table 2. Association of Baseline FACIT-F and Baseline Cytokines 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
*Fatigue, anxiety, depression, sleep disturbance and feeling of well-being cluster 
 
 
 
Table 3. Association of Baseline fatigue cluster and Baseline cytokines 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Change in variables 
with Treatment 
r P-value 
Fatigue(ESAS) -0.49 0.001 
Fatigue 
cluster(FADSW*) 
-0.30 0.04 
IL-6 -0.05 0.55 
IL-1RA 0.04 0.77 
TNF-α 0.07 0.63 
IL-6R 0.07 0.63 
IL-1β 0.21 0.21 
IL-8 -0.1 0.51 
IL-10 0.14 0.38 
TNFR1 -0.04 0.76 
TNFR2 0.05 0.73 
IL-17(L) -0.09 0.53 
IL6/IL10 ratio 0.04 0.80 
Change in variables 
with Treatment 
r P-value 
FACIT-F -0.30 0.04 
Fatigue(ESAS) 0.48 0.001 
IL-6 -0.20 0.18 
IL-1RA -0.02 0.86 
TNF-α -0.05 0.74 
IL-6R -0.13 0.38 
IL-1β -0.14 0.40 
IL-8 0.14 0.34 
IL-10 0.34 0.02 
TNFR1 -0.16 0.28 
TNFR2 -0.26 0.07 
IL-17 0.13 0.40 
IL6/IL10RATIO -.47 0.002 
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Table 4. Association of change in FACIT-F and change in cytokines 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
* Fatigue, anxiety, depression, sleep disturbance and feeling of well-being cluster 
 
 
Table 5. Association of change in fatigue cluster and change in cytokines 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
* Fatigue, anxiety, depression, sleep disturbance and feeling of well-being cluster 
 
Change in variables 
with Treatment 
r P-value 
Fatigue(ESAS) -0.44 0.002 
IL-6 0.08 0.56 
IL-1RA -0.24 0.88 
TNF-α 0.01 0.90 
IL-6R -0.12 0.52 
IL-1β -0.26 0.15 
IL-8 -0.06 0.67 
IL-10 0.14 0.59 
TNFR1 0.39 0.07 
TNFR2 0.17 0.24 
IL-17(L) -0.15 0.34 
IL6/IL10RATIO -0.14 0.38 
ESAS-F CHANGE 0.63 0.0001 
FACIT-F CHANGE -0.396 0.007 
Change in variables 
with Treatment 
r P-value 
   
Fatigue(ESAS) -0.44 0.002 
FADSW* -0.39 0.007 
IL-6 -0.34 0.02 
IL-1RA 0.14 0.37 
TNF-α -0.20 0.17 
IL-6R 0.22 0.13 
IL-1β 0.26 0.16 
IL-8 -0.24 0.37 
IL-10 0.16 0.34 
TNFR1 -0.22 0.16 
TNFR2 -0.19 0.33 
IL-17 -0.05 0.78 
IL6/IL10RATIO -0.14 0.40 
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Table 4 shows change in fatigue was significantly associated with change in the 
levels of serum IL-6 levels after treatment for 15 days. However none of the 
change in serum levels of other inflammatory cytokines was associated with 
change in fatigue after treatment.  
Table 5 shows none of the change in serum levels of other inflammatory 
cytokines was associated with change in fatigue cluster after treatment. TNFRI 
was positively correlated with fatigue cluster with trends towards statistical 
significance(r=0.39, p=0.07). Also interestingly the change in the fatigue scores 
as assessed by FACIT-F is associated with change in fatigue cluster scores. 
 
Exploratory principal component analysis reporting the 1st 4 principal 
components (minimum .50 correlation) shows, baseline CRF (FACIT-F score) 
was associated with IL-6, IL-6R and IL-17, Variance = 78% whereas IL-10, IL-
1RA, TNF-α  and IL-1β were associated with improvement of CRF, 
Variance=74%. Conversely, IL-6 and IL-8 were associated with no improvement 
or worsening of CRF, Variance= 93%. 
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CHAPTER IV. Discussion: 
 
The preliminary findings in this study show the effect of the key mediator for pro-
inflammatory activity cytokine, IL-6 on CRF in patients with advanced cancer. 
With treatment of CRF for 2 weeks, the change in IL-6 negatively correlated with 
change in CRF [as assessed using a FACIT-F subscale scores] (p=0.02).  
 
In our study, baseline CRF scores [FACIT-F subscale] in advanced cancer 
patients were associated with serum levels of IL-6, IL-6R and IL-17 as measured 
by principal component analysis.  With treatment of CRF for 2 weeks, serum 
levels of IL-10, IL-1RA, TNF-α and IL-1β were associated with improvement of 
CRF. Conversely, serum levels of IL-6 and IL-8 were associated with no 
improvement or worsening of CRF.  
 
Findings in our study show increased serum levels of pro-inflammatory cytokines 
with CRF at baseline. These findings are similar to other studies that have shown 
increased serum levels of inflammatory markers in fatigued cancer patients 
before treatment onset and during treatment such as chemotherapy and 
radiotherapy [7, 8, and 50]. In this study we found increased levels of serum 
cytokines IL-6, TNF-α, IL-8, IL-17, and IL-1RA in study patients compared to 
control group [Table 1.d]. However there was no significant difference in the IL- 
1β and IL-10 levels in advanced cancer patients compared to control group. This 
may be due to a methodological issue with IL-1β assay, as most of the IL-1β is in 
the bound form and adequate levels of the IL-1β cannot be detected. Therefore 
IL-1RA may be a more reliable measure of serum IL-1 levels [7].  IL-10 is both an 
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anti and pro-inflammatory cytokine and hence a variable association with fatigue 
scores. Future larger sample studies with advanced cancer patients with no 
fatigue as another cohort is required to validate these important findings. 
 
However In this study there was no direct correlation between baseline fatigue 
scores and baseline serum levels of cytokines. This may be (a) due to the fact 
that they had moderate to severe fatigue prior to fatigue treatment, (b) lack of 
data of serum cytokine levels in patients with advanced cancer with no fatigue. 
(c) Small sample size, and (d) other interactions at baseline such as cancer type 
and prior treatment received may have influence the association between fatigue 
scores and cytokines. 
 
Fatigue is one of the most common and distressing symptoms of cancer and its 
treatment [1-4]. However there are no proven pharmacological treatments 
available to date [58,59]. One main reason is lack of characterization and 
understanding the pathophysiology of CRF [5,7]. As per the current NCCN 
guidelines [60], most studies to date fail to identify the target mechanism. Based 
on the results from our study, a larger study to investigate cytokines IL-6, IL-8, IL-
10, IL-1RA, TNF-α and IL-1β as one of the key target mechanism/common 
denominator is warranted.  
 
We observed a median of 6 point improvement in fatigue scores [FACIT-F 
subscale] after 14 days of treatment. This improvement is above the minimal 
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clinically important difference [MICD] in fatigue score [MICD using FACIT-F 
scores is 3.5points] [61].  
 
Fatigue as measured by FACIT-F fatigue subscale scores correlated with fatigue 
measured ESAS Fatigue item and fatigue cluster (or overall fatigue burden) 
(p<0.05). Moreover, the change in fatigue over time as measured by FACIT-F 
correlated with the change fatigue measured ESAS Fatigue item and fatigue 
cluster (or overall fatigue burden) (p≤0.007). These findings validate the findings 
of a previous study showing the association between fatigue and fatigue clusters 
[35]. 
 
The findings from this study are important as there are no published data 
showing a change in the cytokines with change in CRF with fatigue treatment in 
patients with advanced cancer [7-17]. A pilot work by Monk et al. [62] found 
etanercept, a TNF inhibitor, treatment in solid cancer patients resulted in 
improved fatigue. However the limitation of the study is small sample size and 
lack of data and analysis showing the change in fatigue was due to change in 
serum cytokines levels such as IL-1β, IL-6 or TNF-α.   
 
Another important finding in the study is the association of fatigue cluster with 
serum cytokines IL-10, IL-6/IL-10 (pro-inflammatory and anti-inflammatory ratio). 
In addition, we found that a change in fatigue cluster was significantly associated 
with change in the levels of serum TNF R1 receptor levels after treatment for 14 
days. However the low significance levels (p=0.07) may be due to the small 
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sample size. These findings provide preliminary hypothesis-generating data 
regards to relationship between cytokines constituting the net inflammatory 
burden and net fatigue burden (as defined in terms of fatigue cluster). Further 
studies are needed to validate these findings which may result in finding 
treatments to relieve the net fatigue burden and thus improve quality of life in 
these distressed patients. Future studies should also consider combined anti-
cytokine agents targeting various cytokines with complementary downstream 
signaling pathways that modulate inflammation. This combined modality may 
then reduce the possibility of redundancy, thereby a more sustained control of 
inflammatory cytokines and possible effective improvement of CRF. 
 
Limitations 
 
This study has several limitations. First, the small sample size may have resulted 
in lack of significant association between FACIT-F subscale scores and IL-6, IL-
8, IL-17, IL-10, IL-1β, TNF-α or their receptors at baseline. Second, as the 
dexamethasone study is currently ongoing (121/125 accrued so far), we are 
unable to provide the results of the correlation of the inflammatory cytokines with 
the treatment (dexamethasone or thalidomide) and placebo. We were only able 
to report the change in the inflammatory cytokines with or without improvement of 
CRF in addition to the baseline characteristics of fatigue and cytokines in these 
cohort of advanced cancer patients. However the process of design, methods 
used for the assessment of symptoms and analysis of cytokines were strictly 
followed as per protocol. On conclusion of the dexamethasone trial I will be able 
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to analyze the effect of anti-cytokine agents (dexamethasone or thalidomide) on 
cytokines and fatigue as compared to placebo and publish the results of the data 
of all study patients. Thirdly, fluctuation of cytokine levels and intensity of fatigue 
is common in cancer patients. As only one assessment of fatigue and single 
blood sample was performed at a time point in our study, future studies could 
consider use of multiple blood sampling at different times of the day as well as 
multiple daily assessments of fatigue [7]. 
 
 
Conclusion: 
 
Based on the preliminary analyses CRF score and serum inflammatory cytokines 
of advanced cancer patients, the change in IL-6 negatively correlated with 
change in CRF scores after fatigue treatment. With treatment of CRF for 2 
weeks, serum levels of IL-10, IL-1RA, TNF-α and IL-1β were associated with 
improvement of CRF. Conversely, serum levels of IL-6 and IL-8 were associated 
with no improvement or worsening of CRF. These findings provide important 
preliminary data regards to the role of various inflammatory cytokines have on 
causation of CRF. Future studies are warranted to validate these findings using a 
larger sample so as to develop treatment strategies that target specific cytokines 
that are known to mediate the causation of CRF. 
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Appendix: A 
Memorial Delirium Assessment Scale (MDAS) 
 
INSTRUCTIONS: Rate the severity of the following symptoms of delirium based 
on current interaction with subject 
   Or assessment of his/her behavior or experience over past several hours (as 
indicated in each time.) 
 
ITEM 1-REDUCED LEVEL OF CONSCIOUSNESS (AWARENESS): Rate the 
patient’s current awareness of and 
   Interaction with the environment (interviewer, other people/objects in the room; 
for example; ask patients to 
  Describe their surroundings). 
 0: none (patient spontaneously fully aware of environment and interacts 
appropriately) 
 1: mild (patient is unaware of some elements in the environment, or not 
spontaneously interacting 
  appropriately with the interviewer; becomes fully aware and 
appropriately interactive when 
                                prodded strongly; interview is prolonged but no seriously 
disrupted) 
  2: moderate (patient is unaware of some or all elements in the 
environment, or not spontaneously interacting 
  with the interviewer; becomes in completely aware and 
inappropriately interactive when prodded 
  strongly: interview is prolonged but not seriously disrupted) 
  3: severe (patient is unaware of all elements in the environment with no 
spontaneous interaction of  
   awareness of the interviewer, so that the interview is difficulty-to-
impossible even with maximal 
  prodding 
 
ITEM 2-DISORENTATION: Rate current state by asking the following 10 
orientation items: date, month day, year, 
     Season, floor, name of hospital, city, state, and country. 
  0: none (patient knows 9-10 items) 
  1: mild (patient knows 7-8 items) 
  2: moderate (patient knows 5-6 items) 
  3: severe (patient know no more than 1 item) 
 
ITEM 3-SHORT-TERM MEMORY IMPAIRMENT: Rate current state by using 
repetition and delayed recall of 3 words [patient must immediately repeat and 
recall words 5 min later after an intervening task. Use alternate sets of 3 words 
for successive evaluations (for example, apple, table, tomorrow, sky, cigar, 
justice)]. 
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 0: none (all 3 words repeated and recalled) 
 1: mild (all 3 repeated, patient fails to recall 1) 
 2: moderate (all 3 repeated, patient fails to recall 23) 
 3: severe (patient fails to repeat 1 or more words) 
 
ITEM 4-IMPAIRED DIGIT SPAN: Rate current performance by asking subjects to 
repeat first 3, 4, then 5 digits 
    Forward and then 3, then 4 backwards; continue to the next step only if patient 
succeeds at the previous one. 
 0: none (patient can do at least 5 numbers forward and 4 backward) 
 1: mild (patient can do at least 5 numbers forward and 3 backward) 
 2: moderate (patient can do 4-5 numbers forward, cannot do 3 backward) 
 3: severe (patient can no more than 3 numbers forward) 
 
ITEM 5-REDUCED ABILITY TO MAINTAIN AND SHIFT ATTENTION: As 
indicated during the interview by 
    Questions needing to be rephrased and/or repeated because patient’s 
attention wanders, patient loses track,  
    Patient is distracted by outside stimuli or over-absorbed in a task. 
 0: none (none of the above, patient maintains and shifts attention normally) 
 1: mild (above attentional problems occur once or twice without prolonging 
the interviews) 
 2: moderate (above attentional problems occur often, prolonging the 
interview without seriously disrupting it) 
 3: severe (above attentional problems occur constantly, disrupting and 
making the interview 
  difficult-to-impossible 
 
ITEM 6-DISORGANIZED THINKING: As indicated during the interview by 
rambling irrelevant, or incoherent 
      Speech, or by tangential, circumstantial, or faculty reasoning. Ask patient 
a some a somewhat complex question       (for example, “Describe your 
current medical condition”). 
 0: none  (patient’s speech is coherent and goal-directed) 
 1: mild (patient’s speech is slightly difficult to follow: responses to 
questions are slightly off target but not 
       so much as to prolong the interview) 
 2: moderate (disorganized thoughts or speech are clearly present, such 
that interview is prolonged but not 
                                    disrupted) 
 3: severe (examination is very difficult or impossible due to disorganized 
thinking or speech) 
 
 
Appendix 1 
Memorial Delirium Assessment Scale (MDAS)o 1996 
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ITEM 7-PERCEPTUAL DISTURBANCE: Misperceptions, illusions, hallucinations 
inferred from inappropriate 
    behavior during the interview or admitted by subject, as well as those elicited 
from nurse/family/chart accounts of       
    the past several hours or of the time since last examination: 
 0: none (no misperceptions, illus9ions, or hallucinations) 
 1: mild (misperceptions or illusions related to sleep, fleeting hallucinations 
on 1-2 occasions without 
                                inappropriate behavior) 
 2: moderate (hallucinations or frequent illusions on several occasions 
with minimal inappropriate behavior 
                                that does not disrupt the interview) 
 3: severe (frequent or intense illusions or hallucinations with persistent 
inappropriate behavior that  
  disrupts the interview or interferes with medical care) 
ITEM 8-DELUSIONS: Rate decisions inferred from inappropriate behavior 
during the interview on admitted by the    patient, as well as delusions elicited 
from nurse/family/chart accounts of the past several hours of the time 
    Since the previous examination. 
 0: none (no evidence of misinterpretations on delusions) 
 1: mild (misinterpretation or suspiciousness without clear delusional ideas 
or inappropriate behavior) 
                                marginally disrupt the interview of interfere with medical 
care) 
 2 moderate (delusions admitted by the patient or evidenced by his/her 
behavior that do not or only  
                                marginally disrupt the interview or interfere with medical 
care) 
 3: severe (persistent and/or intense delusions resulting in inappropriate 
behavior, disrupting the interview 
                                 or seriously interfering with medical care) 
 
ITEM 9-DECREASED OR INCREASED PSYCHOMOTOR ACTIVITY: Rate 
activity over past several hours, as well as activity during interview by circling 
(a) hypoactive, (b) hyperactive, or (c) elements of both present. 
 0: none (normal psychomotor activity) 
 a b c 1: mild (hypoactivity is barely noticeable , expressed as lightly 
slowing of movement. Hyperactive is  
                                barely noticeable or appears as simple restlessness. 
 a b c   (Hypoactivity is undeniable, with marked reduction in the 
number of movements or marked 
      2: moderate       slowness of movement, subject rarely spontaneously moves 
or speaks. Hyperactivity is 
                                undeniable, subject moves almost constantly; in both cases, 
exam is prolonged as a 
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   consequence.) 
 a b c 3: severe (Hypoactivity is severe, patient does not move or speak 
without prodding or is catatonic. 
                                Hyperactivity is severe, patient is constantly moving, 
overreacts to stimuli, requires surveillance    
                                and/or restraint, getting through the exam is difficult or 
impossible .) 
 
ITEM 10-SLEEP-WAKE CYCLE DISTURBANCE (DIORDER OF AROUSAL): 
Rate patient’s ability to either sleep 
    Or stay awake at the appropriate times. Utilize direct observation during the 
interview, as well as reports from  
    Nurses, family, patient, or charts describing sleep-wake cycle disturbance over 
the past several hours or since last 
    Examination.  Use observations of the previous night for morning evaluations 
only. 
 0: none (at night sleeps well; during the day, has no trouble staying awake) 
 1: mild (mild deviation from appropriate sleepfulness and wakefulness 
states at night, difficulty falling 
  asleep or transient night awakenings, needs medication to sleep 
well; during the day, reports 
  periods of drowsiness or, during the interview, is drowsy but can 
easily awaken him/ 
  herself) 
 2: moderate (moderate deviations from appropriate sleepfulness and 
wakefulness states at night, repeated and 
  prolonged night awakening, during the day, reports of frequent and 
prolonged napping or, 
  during the interview, can only be roused to complete wakefulness 
by strong stimuli) 
 3: severe (severe deviations from appropriate sleepfulness and wakefulness 
states, at night, sleeplessness 
                 during the day, patient spends most of the time sleeping or 
during the interview cannot be  
  roused to full wakefulness by any stimuli) 
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     Appendix: D    
 
METHODS OF CYTOKINE ASSESSMENT 
Serum preparation 
Collect whole blood in a preservative-free and anticoagulant free (red top) 
Vacutainer tube (Becton-Dickinson). After collection of the whole blood, allow the 
blood to clot by leaving it undisturbed at room temperature. This usually takes 
15-30 minutes. Remove the clot by centrifuging at 1,000-2,000 x g for 10 minutes 
in a refrigerated centrifuge. The resulting serum supernatant is immediately 
transferred into a clean polypropylene tube using a Pasteur pipette. The samples 
should be maintained at 2-8°C while handling. If the serum is not analyzed 
immediately, the serum will be apportioned into 0.5 mL aliquots in a Nunc 
cryovial and stored and transported at –20°C or lower. It is important to avoid 
freeze/thaw cycles because this is detrimental to many serum components. 
Samples that are hemolyzed, icteric, or lipemic can invalidate certain tests, and 
may need to be re-collected. All serum samples were frozen at –80 °C until ready to 
assay them in batch. The frozen serum samples were be rapidly thawed and 
brought to room temperature just before they are to be assayed for cytokines. . 
Determination of Cytokines by Luminex Multiplex Cytometric 
Bead Array Assay 
Principles of the Method 
• Beads of defined spectral properties conjugated to analyte specific 
capture antibodies and samples (including standards of known analyte 
concentration, control specimens, and unknowns) are pipetted into the 
wells of a filter bottom micro titer well plate and incubated for 2 hours.  
• During this first incubation, analytes bind to the capture antibodies on 
the beads. After washing the beads, analyte-specific biotinylated 
detector antibodies are added and incubated with the beads for 1 hour.  
• During the second incubation, the analyte-specific biotinylated detector 
antibodies recognize their epitopes and bind to the appropriate 
immobilized analytes. After removal of excess biotinylated detector 
antibodies, streptavidin conjugated to the fluorescent protein, R-
Phycoerythrin (Streptavidin-RPE), is added and incubated for 30 
minutes.  
• During this final incubation, the Streptavidin-RPE binds to the 
biotinylated detector antibodies associated with the immune complexes 
on the beads, forming a four-member solid phase sandwich.  
• After washing to remove unbound Streptavidin-RPE, the beads are 
analyzed with the Luminex 100™ instrument. By monitoring the 
spectral properties of the beads and the amount of associated R-
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Phycoerythrin (RPE) fluorescence, the concentration of one or more 
analytes can be determined. 
Preparation of Standard 
Reconstitute the protein standard within one hour of performing the assay. All 
standards are calibrated to NIBSC preparations, when available. Additional 
standards are available from BioSource, Carlsbad, CA. The standard included in 
the kit is provided as a premixed set of related markers. The concentrations of 
the protein components of the standard are indicated on the information sheet 
included in the kit. Standard dilutions may be performed in glass or plastic tubes. 
When using serum or plasma samples, reconstitute the standard with Assay 
Diluent provided. Protein standards may be analyzed alone, or may be combined 
with other protein standards for higher levels of multiplexing.  
Assay Procedure (Figure A, adapted from 
BioSource, Invitrogen, Carlsbad, CA ) 
1. Pre-wet the wells designated for the 
assay. Pipette 0.2 mL of Working 
Wash Solution into designated wells. 
Wait 15 to 30 seconds then aspirate 
the Working Wash Solution from the 
wells using the vacuum manifold. 
Wells not used during the assay 
should be kept dry for future use. An 
adhesive plate cover may be used to 
seal the unused wells. 
2. Vortex the diluted bead solution for 30 
seconds, then sonicate for at least 30 
seconds immediately prior to use in 
the assay. 
3. Pipette 25 µL of the diluted bead 
solution into each well. Once the 
beads are added to the plate, keep the 
plate shielded from light. 
4. Add 0.2 mL Working Wash Solution to 
the wells. Allow the beads to soak for 
15 to 30 seconds, and then remove 
the Working Wash Solution from the 
wells by aspiration with the vacuum 
manifold. Repeat this washing step. Blot residual liquid from the bottom of the 
plate on clean paper towels. 
5. Pipette 50 µL Incubation Buffer into each well. 
6. To the wells designated for the standard curve, pipette 100 µL of appropriate 
standard dilution. 
7. To the wells designated for the sample, pipette 50 µL Assay Diluent followed by 
Fig A. Multiplex Assay Procedures(Adapted from 
Biosource, Invitrogenm Carlsba, CA) 
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50 µL sample. 
8. Incubate the plate for 2 hours at room temperature on an orbital shaker. 
Shaking should be sufficient to keep beads suspended during the incubation 
(500-600 rpm). 
9. Ten to fifteen minutes prior to the end of this incubation, prepare the 
biotinylated detector antibody in accordance with instruction. 
10. After the 2 hour capture bead incubation, remove the liquid from the wells by 
aspiration with the vacuum manifold. Add 0.2 mL Working Wash Solution to the 
wells. Allow the beads to soak for 15 to 30 seconds, then aspirate with the 
vacuum manifold. Repeat this washing step. Blot residual liquid from the bottom 
of the plate on clean paper towels. 
11. Add 100 µL of 1x stock, diluted Biotinylated Detector Antibody to each well and 
incubate the plate for 1 hour at room temperature on an orbital shaker. Shaking 
should be sufficient to keep the beads suspended during incubation (500-600 
rpm). 
12. Ten to fifteen minutes prior to the end of the detector incubation step, prepare 
the Streptavidin-RPE in accordance with instruction. 
13. Remove the liquid from the wells by aspiration with the vacuum manifold. Add 
0.2 mL Working Wash Solution to the wells. Allow the beads to soak for 15 to 
30 seconds, then aspirate with the vacuum manifold. Repeat this washing step. 
Blot residual liquid from the bottom of the plate on paper towels. 
14. Add 100 µL of 1x stock, diluted Streptavidin-RPE to each well and incubate the 
plate for 30 minutes at room temperature on an orbital shaker. Shaking should 
be sufficient to keep the beads suspended during incubation (500-600 rpm). 
15. Prepare the Luminex 100 instrument during this incubation step. 
16. Remove the liquid from the wells by aspiration with the vacuum manifold. Wash 
the beads by adding 0.2 mL Working Wash Solution to the wells; allow the 
beads to soak for 10 seconds, then aspirate with the vacuum manifold. Repeat 
this washing step two additional times for a total of 3 washes. 
17. Add 100 µL of Working Wash Solution to each well. Shake the plates on an 
orbital shaker (500-600 rpm) for 2-3 minutes to resuspend the beads. If the 
plates cannot be read on the day of the assay, they may be covered and stored 
in a dark location overnight at 2 °C to 8 °C for reading the following day without 
significant loss of fluorescent intensity. Aspirate Working Wash Solution from 
stored plates and add 100 µL fresh Working Wash Solution. Place the plate on 
an orbital shaker 2-3 minutes prior to analysis. 
18. Uncover the plate; insert the plate into the XY platform of the Luminex 100 
instrument, and analyze the samples. 
19. Determine the concentration of samples from the standard curve using curve-
fitting software. The four-parameter algorithm usually provides the best fit. 
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Measurement of Serum Cytokines by ELISA 
Principle of the assay 
• This assay employs the quantitative sandwich enzyme immunoassay 
technique. Each well of the 96 wells of a micro titer well plate is pre-coated 
with a monoclonal antibody specific for a cytokine.  
• Standards and samples are pipetted into the wells and the immobilized 
antibody binds the particular cytokine.  
• After washing away any unbound substances, an enzyme-linked 
monoclonal antibody specific for a cytokine is added to the wells. 
• Following a wash to remove any unbound antibody-enzyme reagent, a 
substrate solution is added to the wells and color develops in proportion to 
the amount of cytokine bound in the initial step.  
• The color development is stopped and the intensity of the color is 
measured. The concentration of the analyte is directly proportional to the 
intensity of the color of the enzymatic reaction. 
Assay procedure 
1. Warm up all reagents, working standards, and samples to room 
temperature. 
2. Add 50 µL of Assay Diluent to each well. 
3. Add 200 µL of Standard, control, or sample per well. Cover with the 
adhesive strip provided with the kit. Incubate for 2 hours at room 
temperature.  
4. Aspirate each well and wash, repeating the process three times for a total 
of four washes. Wash each well by filling each well with Wash Buffer (400 
µL) using a squirt bottle, manifold dispenser or automatic washer. 
Complete removal of liquid at each step is essential to good performance. 
After the last wash, remove any remaining Wash Buffer by aspirating or 
decanting. Invert the plate and blot it against clean paper towels. 
5. Add 200 µL of Conjugate to each well. Cover with a new adhesive strip. 
6. Incubate for 2 hours at room temperature. 
7. Repeat the aspiration/wash as in step 5. 
8. Add 200 µL of Substrate Solution to each well. Protect from light. Incubate 
for 30 minutes at room temperature. 
9. Add 50 µL of Stop Solution to each well. If color change does not appear 
uniform, gently tap the plate to ensure thorough mixing. 
10. Determine the optical density of each well within 30 minutes, using a 
microplate reader set to 450 nm. If wavelength correction is available, set 
to 540 nm or 570 nm. If wavelength correction is not available; subtract 
readings at 540 nm or 570 nm from the readings at 450 nm. This 
subtraction will correct for optical imperfections in the plate. Readings 
made directly at 450 nm without correction may be higher and less 
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accurate. 
11. Create a standard curve by reducing the data using computer software 
capable of generating a four parameter logistic (4-PL) curve-fit. As an 
alternative, a standard curve will be constructed by plotting the mean 
absorbance for each standard on the y-axis against the concentration on 
the x-axis and drawing a best-fit curve through the points on the graph. 
Plotting the log of cytokine concentrations versus the log of optical density 
(OD) may linearize the data, and the best-fit line can be determined by 
regression analysis. This procedure produces an adequate but less 
precise fit of the data. If samples have been diluted, concentrations read 
from the standard curve will be multiplied by the dilution factor. 
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Appendix: E  
Study consent 
INFORMED CONSENT/AUTHORIZATION FOR PARTICIPATION IN 
RESEARCH WITH OPTIONAL PROCEDURES 
 
The Effect of Dexamethasone on Symptoms in Patients with Advanced 
Cancer 
2005-0816 
 
 
Study Chair: Sriram Yennurajalingam 
 
 
1
. 
    
 Participant’s Name  Medical Record Number 
 
 
 
You are being asked to take part in this clinical research study at The 
University of Texas M. D. Anderson Cancer Center ("M. D. Anderson").  
This consent form explains why this research study is being done and 
what your role will be if you choose to take part. This form also 
describes the possible risks connected with being in this study.  After 
reviewing this information with the person responsible for your 
enrollment, you should know enough to be able to make an informed 
decision on whether you want to take part in the study. 
 
You are being asked to take part in this study because you have 
advanced cancer and are experiencing weight loss, fatigue, pain, 
nausea, loss of appetite, sleep problems, and/or depression. 
 
 
DESCRIPTION OF RESEARCH 
 
 
2. PURPOSE OF STUDY 
 
The goal of this clinical research study is to learn if dexamethasone 
can help to control symptoms such as fatigue, pain, nausea, weight 
loss, loss of appetite, sleep problems, and/or depression in patients 
with advanced cancer. 
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Optional Procedures:  You will be asked to allow blood to be drawn 
for tests to study how levels of certain proteins in your blood (called 
cytokines), white blood cells (called monocytes) and cell receptors for 
these proteins are affected by taking dexamethasone and how this 
may change the symptoms you have. 
 
You are being asked to complete a questionnaire on the quality of your 
sleep. 
 
You are being asked to give saliva samples to check your level of 
cortisol. Cortisol is a hormone that may be affected by sleep pattern 
changes.  
 
 
3. DESCRIPTION OF STUDY 
 
Dexamethasone decreases inflammation and also suppresses the 
immune system.  
 
Before you can start treatment on this study, you will have what are 
called "screening tests".  These tests will help the doctor decide if you 
are eligible to take part in this study.  You will answer questions about 
your diagnosis, the medication you are taking, and the symptoms you 
are having (for example, pain, fatigue, nausea, appetite problems, 
sleep problems, depression, and your overall feeling of well-being).  
Blood (about 1 tablespoon) will be drawn to measure protein levels.  
The blood work for protein levels and iron are screening tests and 
done at baseline to see if you have too little iron in your blood.   Blood 
will be drawn to test hemoglobin levels (about 1 tablespoon).    It will 
take about 30 minutes to complete all the screening tests. 
 
If you are found to be eligible for this study, you will be randomly 
assigned (as in the toss of a coin) to receive either dexamethasone or 
a placebo by mouth in the morning and at night with food every day for 
14 days.  A placebo is a substance that looks like the study drug but 
which has no active ingredients. You will have an equal chance of 
being placed in either of the 2 groups.  You, the medical staff, and 
researchers will not know to which group you have been assigned.  
 
Beginning on Day 15 [± 3 days], regardless of if you were assigned to 
the dexamethasone or placebo group during the first 14 days, you will 
begin receiving the dexamethasone.  On Days 15-21, you will receive 
dexamethasone 2 times a day. On Days 22-28 you will continue to 
take dexamethasone 2 times a day, but it will be at a lower dose level. 
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If you develop intolerable side effects while on this study, the 
medication will be stopped and you will be removed from the study.   
 
You will be asked to return to the outpatient clinic on Days 8 [± 3 days], 
15 [± 3 days] , 22 [± 3 days], and 29 [± 3 days] to answer a 
questionnaire about your cancer diagnosis, the medication you are 
taking, and the symptoms you are having (for example, pain, fatigue, 
nausea, appetite problems, sleep problems, depression, and your 
overall sense of well-being).   The questionnaire will take 
approximately 30 minutes to complete.   Blood (about 1 tablespoon) 
will be drawn to measure protein levels and to check the iron level in 
your blood.   If you are unable to return to the clinic on days 8, 15, 22, 
or 29; the assessments will be done by the research nurse by phone; 
the blood work will not be done. 
 
You will be considered off-study on Day 29 [ ± 3 days]. All study 
patients will have a 2 week follow-up on day 43 [± 3 days] after study 
drug has been discontinued,  for safety and toxicity assessments. If 
you are unable to return to the clinic on day 43, the research nurse will 
do the safety and toxicity assessment by phone. 
 
This is an investigational study.  Dexamethasone has been 
approved by the FDA and is a commercially available drug.  It is FDA 
approved at this dose level.  Its use in this study, for this purpose, is 
investigational.  Dexamethasone will be provided free of charge during 
this study up to Day 29.  It can continue to be prescribed to you by 
your primary doctor after that time, if needed, but you and/or your 
insurance provider will then be responsible for the cost of the 
dexamethasone.  About 125 patients will take part in this study. Up to 
75 will be enrolled at M. D. Anderson.  The other sites participating in 
this study are Lyndon Baines Johnson [LBJ] breast oncology clinic 
Houston Texas, and Four Seasons Hospice in Flat Rock, North 
Carolina. 
 
Optional Procedures:  If you agree, extra blood (about 1 tablespoon 
each time) will be drawn and used to study the effect dexamethasone 
has on proteins in your blood (called cytokines), white blood cells 
(called monocytes) and cell receptors for these proteins and how 
changes in these proteins affect the symptoms you have.  This blood 
will be drawn on Days 8, 15, 22, and 29. If you are unable to return to 
the clinic the blood work will not be done. 
 
If you agree, you will complete a questionnaire at the beginning of the 
study and on Day 15. The questionnaire asks questions about sleep 
quality, including bed time, length of time to fall asleep, and symptoms. 
It takes about 5 minutes to complete. 
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You will also be asked to provide a saliva sample to test for cortisol 
levels at the beginning of the study  and on Day 15.  You will be given 
detailed instructions on how to collect the saliva samples. 
 
There will be no cost to you for taking part in the optional procedures.  
 
You do not have to agree to take part in the optional procedures in 
order to receive treatment on this study. 
 
 
4. RISKS, SIDE EFFECTS, AND DISCOMFORTS TO PARTICIPANTS 
 
While on this study, you are at risk for the side effects listed in this 
form.  You should discuss these with the study doctor or your regular 
doctor.  The known side effects are listed in this form, but they will vary 
from person to person.  Many side effects go away shortly after the 
study drug is stopped, but in some cases side effects may be serious, 
long lasting, and/or permanent and may even cause death. 
 
Dexamethasone Side Effects 
 
It is not known how often the side effects of dexamethasone may 
occur. 
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rregular heartbeat 
slow heartbeat 
cardiac arrest (sudden 
stopping of the heart) 
enlarged heart 
heart failure 
swelling 
high blood pressure  
tearing of the walls of the 
heart 
fainting 
shock 
depression 
unstable emotions 
euphoria (abnormal 
feelings of great happiness 
or well-being) 
headache 
increased pressure 
between the skull and brain 
(possible headache) 
difficulty sleeping 
weakness 
mood swings 
nerve inflammation  
personality changes 
psychotic disorders 
seizures 
dizziness 
acne 
skin inflammation 
hair loss 
tissue swelling 
bruising 
dry skin 
skin redness 
lightening and/or darkening 
of the skin 
fragile skin 
excessive/increased hair 
growth 
spots under the skin 
skin rash 
skin thinning  
skin tests (such as for TB) 
may not be accurate 
decreased function of 
the adrenal glands, 
which could affect the 
body's ability to control 
blood pressure and/or 
react to stress 
increased hormone 
production (possible 
difficulty managing 
weight and muscle 
weakness) 
diabetes 
abnormal blood sugar 
test (also known as 
"pre-diabetes")  
stunted growth in 
children 
high blood sugar 
(possible diabetes) 
low blood levels of 
potassium (possibly 
due to fluid loss) 
low levels of nitrogen  
abnormal hormone 
production (possible 
fatigue, difficulty 
managing weight, 
and/or problems 
fighting infection) 
abnormal breakdown of 
proteins 
high blood levels of 
sodium (possible 
weakness and/or 
swelling) 
bleeding in the 
digestive system 
abdominal swelling 
anal itching 
increased appetite 
hole in the stomach 
and/or intestines, which 
may cause the contents 
to leak 
nausea 
inflammation of the 
changes to the 
menstrual cycle 
abnormal sperm 
development  
blood clot blocking a 
blood vessel (possible 
stroke) 
blood vessel 
inflammation (possible 
fever and/or fatigue)  
inflammation of a vein 
caused by blood clot  
enlarged liver 
abnormal liver tests 
(possible liver damage) 
joint disease and/or 
pain 
death of bone tissue 
broken bones  
loss of muscle mass  
muscle disease that 
causes weakness 
nervous system 
disease (possible pain 
and/or weakness) 
decreased bone 
density (possible 
fractures) 
tickling/tingling 
sensation 
rip in a tendon 
abnormal fat deposit  
collapse of spinal 
bones 
cataracts (clouding of 
the lens of the eye) 
bulging eye 
increased pressure in 
the eye (possible loss 
of vision) 
high levels of sugar in 
the urine 
build-up of fluid in the 
lungs 
allergic reaction 
(possibly severe) 
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stretch marks 
hives 
sweating 
decrease in carbohydrate 
tolerance  
pancreas (possible 
abdominal pain) 
sore in the stomach, 
small intestine, and/or 
esophagus 
weight gain 
poor blood supply and 
death of tissue 
hiccups 
infection 
moon face 
new occurrence of 
cancer  
malignant skin lesions 
wound healing 
problems 
 
 
Questionnaires may contain questions that are sensitive in nature.  
You may refuse to answer any question that makes you feel 
uncomfortable.  If you have concerns after completing the 
questionnaire, you are encouraged to contact your doctor or the study 
chair. 
 
Blood draws may cause pain, bleeding, and/or bruising.  You may 
faint and/or develop an infection with redness and irritation of the vein 
at the site where blood is drawn.  Frequent blood collection may cause 
anemia (low red blood cell count), which may create a need for blood 
transfusions. 
 
This study may involve unpredictable risks to the participants. 
 
Optional Procedures:  You may experience pain, bleeding, and/or 
bruising from the blood draws.  You may faint and/or develop an 
infection with redness and irritation of the vein at the site where blood 
is drawn.  Frequent blood collection may cause anemia (low red blood 
cell count), which may create a need for blood transfusions. 
 
Questionnaires may contain questions that are sensitive in nature.  
You may refuse to answer any question that makes you feel 
uncomfortable.  If you have concerns after completing the 
questionnaire, you are encouraged to contact your doctor or the study 
chair. 
 
 
5. POTENTIAL BENEFITS 
 
Treatment on this study may help to control your symptoms.  
Future patients may benefit from what is learned from this study.   
There may be no benefits for you in this study. 
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Optional Procedures:  There are no benefits to you for taking part in 
the optional procedure.  Future patients may benefit from what is 
learned. 
 
 
6. ALTERNATE PROCEDURES OR TREATMENTS 
 
You may choose not to take part in this study.  You may chose to take 
dexamethasone outside of this study.  You may choose other 
investigational therapy, if available.  You may choose not to have 
treatment for you symptoms of fatigue, pain, nausea, depression or 
loss of appetite at all.  Refusal to take part in this study will not cause 
penalty or loss of benefits to which you are otherwise entitled. 
 
Optional Procedures:  Treatment with the study drug may be given 
without taking part in the optional procedures. 
 
I understand that the following statements about this study are 
true: 
 
7. M. D. Anderson may benefit financially from my participation and/or 
from what is learned in this study. 
 
8. This study is supported by:  American Cancer Society (Mentored 
Research Scholar Grant). 
 
9. I may ask the study chair any questions I have about this study, 
including questions about the costs.  I may contact the study chair, Dr. 
Sriram Yennurajalingam, at 713-792-6085.  I may also contact the 
Chair of M. D. Anderson's IRB at 713-792-2933 with any questions 
that have to do with this study or my rights as a study participant. 
 
10. My participation in this research study is strictly voluntary.  I may 
refuse to take part in this study without any penalty or loss of benefits 
to which I am otherwise entitled.  I may also withdraw from 
participation in this study at any time without any penalty or loss of 
benefits.  I should first discuss leaving the study with my doctor.  If I 
withdraw from this study, I may still be treated at M. D. Anderson. 
 
11. I understand that the study may be changed or stopped at any time by 
the study chair, American Cancer Society (Mentored Research 
Scholar Grant), the U.S. Food and Drug Administration (FDA), the 
Office for Human Research Protections (OHRP) (a regulatory agency 
that oversees research in humans), or the IRB of M. D. Anderson. 
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12. I will be informed of any new findings that might affect my willingness 
to continue taking part in the study. 
 
13. M. D. Anderson will take appropriate steps to keep my personal health 
information private.  However, there is no guarantee of absolute 
privacy.  Federal agencies (such as the FDA and the OHRP), 
American Cancer Society (Mentored Research Scholar Grant), and 
the IRB of M. D. Anderson might review my record to collect data or to 
check that the research is being done safely and correctly.  In some 
situations, the FDA could be required to reveal the names of 
participants. 
 
14. If I suffer injury as a direct result of taking part in this study, M. D. 
Anderson will provide medical care.  However, this medical care will 
be billed to my insurance provider or me in the ordinary manner.  I 
understand that I will not be reimbursed for expenses or compensated 
financially by M. D. Anderson or American Cancer Society (Mentored 
Research Scholar Grant) for this injury.  I may also contact the Chair 
of M. D. Anderson’s IRB at 713-792-2933 with questions about study-
related injuries. 
 
15. Certain tests, procedures, and/or medications that I may receive as 
part of this study may be without cost to me because they are for 
research purposes only.  However, my insurance provider or I may be 
financially responsible for the cost of supportive care and treatment of 
any complications resulting from the research tests, procedures, 
and/or medications, including hospitalization, nausea, vomiting, low 
blood cell counts, and dehydration.  Standard medical care that I 
receive under this research study will be billed to my insurance 
provider and/or me in the ordinary manner.  I should learn before 
taking part in this study which parts of the research-related care will 
be provided without charge, which costs my insurance provider will 
pay for, and which costs will be my responsibility.  I may ask to speak 
with a financial counselor about the costs of this study. 
 
16. I understand that there are no plans to compensate me for any 
patents or discoveries that may result from my participation in this 
research.  I will receive no compensation for taking part in this study. 
 
Authorization for Use and Disclosure of Protected Health 
Information: 
 
A. During the course of this study, the research team at M. D. Anderson 
will be collecting information about you.  This information may include 
your medical history, study schedule, and the results of any of your 
tests, therapies, and/or procedures.  The purpose of collecting and 
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sharing this information is to learn about how the study procedures 
may affect the disease and any study-related side effects. Your doctor 
and the research team may share your study information with the 
parties named in Section E below.   
 
B. If you refuse to provide your authorization to disclose your protected 
health information, you will not be able to participate in this research 
study. 
 
C. Your protected health information will be protected according to state 
and federal law.  However, there is no guarantee that your information 
will remain confidential, and it may be re-disclosed at some point. 
 
D. All identifying information such as your name and address will be kept 
private. This information may be kept at M. D. Anderson forever.  You 
will be assigned a code number so that your name will not be used. 
The research team at M. D. Anderson will be able to link the code 
number to your name.  In some instances, in order to ensure the 
scientific value of the study, the parties named in Section E below will 
be able to view your study record but will not be permitted to copy any 
identifying information contained in your record. 
 
E. Your information may be shared with the following parties:  
 
American Cancer Society (Mentored Research Scholar Grant) 
The FDA 
The OHRP  
The IRB of M. D. Anderson 
Officials of M. D. Anderson 
Clinical study monitors who verify the accuracy of the information 
Individuals with medical backgrounds who determine the effect that 
the study procedures may have on the disease 
Individuals who put all the study information together in report form 
 
F. You have the right to see and reproduce your records related to the 
research study, and ask for corrections, for as long as this information 
is held by the study chair and/or M. D. Anderson.  However, in some 
studies, in order to ensure the scientific value of the study, 
participants are not able to view or reproduce their study records until 
the research has been completed with all participants in the study.  If 
possible for this study, your doctor will be able to discuss your clinical 
test results with you. 
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G. There is no expiration date for the use of your protected health 
information.  You may withdraw your authorization to share your 
protected health information at any time in writing.  Instructions on 
how to do this can be found in the M. D. Anderson Notice of Privacy 
Practices (NPP).  You may contact the IRB Staff at 713-792-2933 with 
questions about how to find the NPP.  If you withdraw your 
authorization, you will be removed from the study and the study chair 
and staff will no longer use or disclose your protected health 
information in connection with this study, unless the study chair or 
staff needs to use or disclose some of your research-related protected 
health information to preserve the scientific value of the study.  The 
parties listed in Section E above may use any study data that were 
collected before you canceled your authorization. 
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CONSENT/PERMISSION/AUTHORIZATION 
FOR TREATMENT AND OPTIONAL PROCEDURES 
 
(Mark choice(s) with an "X") 
 
I elect to ____ or not to ____ extra blood to be drawn as an optional 
procedure. 
Participant's Initials ________ 
 
I elect to ____ or not to ____ complete questionnaires as an optional 
procedure. 
Participant's Initials ________ 
 
I elect to ____ or not to ____ allow saliva to be collected  as an optional 
procedure. 
Participant's Initials ________ 
 
 
Having read and understood the above and having had the chance to ask 
questions about this study, think about the study, and talk with others as 
needed, I give the study chair permission to enroll me on this study.  By 
signing this consent form, I am not giving up any of my legal rights.  I have 
been given a signed copy of this consent document. 
 
SAMPLE -- NOT FOR USE IN CONSENTING PATIENTS 
SIGNATURE OF PARTICIPANT   
DATE 
 
 
I was present during the explanation of the research to be performed 
under Protocol 2005-0816. 
 
SAMPLE -- NOT FOR USE IN CONSENTING PATIENTS 
SIGNATURE OF WITNESS TO THE VERBAL CONSENT 
PRESENTATION (OTHER THAN PHYSICIAN OR STUDY 
CHAIR) 
  
DATE 
 
 
SAMPLE -- NOT FOR USE IN CONSENTING PATIENTS 
SIGNATURE OF PERSON  RESPONSIBLE & RELATIONSHIP   
DATE 
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I have discussed this clinical research study with the participant and/or his 
or her authorized representative, using language that is understandable 
and appropriate.  I believe that I have fully informed this participant of the 
nature of this study and its possible benefits and risks and that the 
participant understood this explanation. 
 
SAMPLE -- NOT FOR USE IN CONSENTING PATIENTS 
SIGNATURE OF STUDY CHAIR OR PERSON OBTAINING 
CONSENT 
  
DATE 
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Translator 
 
I have translated the above informed consent as written (without additions or 
subtractions)  
into _____________________________ and assisted the people 
obtaining/providing 
 (Name of Language) 
consent by translating all questions and responses during the consent 
process for this participant. 
 
SAMPLE -- NOT FOR USE IN CONSENTING PATIENTS 
 
NAME OF TRANSLATOR 
  
SIGNATURE OF TRANSLATOR 
  
DATE 
 
 
 
 Please check here if the translator was a member of the research 
team.  (If checked, a witness, other than the translator, must sign the 
witness line.) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 60 
 
 
Appendix F:  
 
Treatment Plan and Standard operating procedure: 
 
This is a prospective, randomized double blind, placebo controlled study 
comparing the effect of dexamethasone versus placebo.  We will randomize 125 
eligible patients to receive either dexamethasone 4 mg orally two times a day for 
14 days or matching placebo.  During the study period, patients will be assessed 
for the intensity of fatigue, other symptoms and toxicities.  Patients will also be 
assessed by the research nurses for any signs and symptoms of infection while 
on the study drug.  Patients will undergo laboratory tests to measure cytokines. 
 
A physician will do a physical exam on the patient on day 0, 15, and Day 29; If 
patient is unable to return to clinic on Day 8, 15, 22, or 29 the assessments will 
be done by the research nurse by phone.   Laboratory correlates including 
cytokine levels- IL-1, IL-6, IL-17 TNF-alpha, IL-10, IL-8, and corresponding 
receptor levels, will be performed at baseline, Day 15 [ ± 3 days], and Day 29 [ ± 
3 days. Patients will also be assessed by the research nurses for any signs and 
symptoms of infection while on the study drug.    
 
All study patients will be asked to return to the clinic for follow-up assessments 2 
weeks after the study medication is discontinued ( day 43 ± 3 days) for a safety 
and toxicity assessment.  If the patient is unable to return to the clinic on day 43, 
the safety and toxicity assessment will be done by the research nurse by 
telephone 
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